
Serum Institute’s Cervavac Receives WHO Prequalification
The story in brief
The World Health Organization prequalified Cervavac, India’s first gender-neutral HPV vaccine, enabling UN agencies to procure it. Developed by SII with global partners, the vaccine targets four HPV types and is approved for ages nine to 26. This marks SII’s 32nd WHO prequalification milestone. The vaccine aims to prevent HPV-related diseases globally.